期刊
CLINICAL THERAPEUTICS
卷 37, 期 12, 页码 2866-2877出版社
ELSEVIER
DOI: 10.1016/j.clinthera.2015.10.001
关键词
Thalassemia major; iron overload; iron chelators; labile plasma iron
Purpose: Iron chelation has improved survival and quality of life of patients with thalassemia major. there are currently 3 commercially available iron-chelating drugs with different pharmacokinetic and pharmacodynamic activity. The choice of adequate chelation treatment should be tailored to patient needs and based on up-to-date scientific evidence. Methods: A review of the most recent literature was performed. Findings: The ability of the chelators to bind the redox active component of iron, labile plasma iron, is crucial for protecting the cells. Chelation therapy should be guided by magnetic resonance imaging that permits the tailoring of therapy according to the needs of the patient because different chelators preferentially clear iron from different sites. Normal levels of body iron seem to decrease the need for hormonal and cardiac therapy. (C) 2015 Elsevier HS Journals, Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据